Pancreatic Cancer is the 3rd
Leading Cause of Cancer Death

There is an unmet need in oncology for new biomarkers that can be used as early detection tools and for guiding treatment. Reccan Diagnostics has a strong scientific expertise in identifying protein targets specific for clinical application using state-of-the-art mass spectrometry and validation by orthogonal platforms like tissue microarray, immunohistochemistry and ELISA. Proteomic studies includes various technical disciplines, where Reccan Diagnostics has cutting edge capability and experience. In particular, we have have adopted the use of Parallel Reaction Monitoring Mass Spectrometry (PRM-MS) on which a high throughput platform has been built for rapid screening of samples in a simultaneously cost efficient, quantitative and extremely accurate way.
Technology
Clinical studies & sample repository
Disease treatments will in the future be entirely dependent on precision diagnostics that will enable diagnosis at an earlier stage and identification of responders to treatment. Reccan Diagnostics has access to high quality clinical biobank material (blood and tissue) combined with extensive register data for patients and a cutting edge mass spectrometric technology, which provides optimal possibilities to develop diagnostic assays. This provides the opportunity to develop a variety of products for various indications:
-
screening
-
diagnosis
-
staging and prognosis
-
probe for diagnostic imaging
-
prediction of treatment response (companion diagnostics)

Publications
-
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer
-
Targeting dendritic cells in pancreatic ductal adenocarcinoma
-
Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma
-
Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment
-
Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?
-
Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma
-
Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma
-
Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer
-
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer